Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of advanced NSCLC.

- Stage III with pleural effusion and stage IV.

- Patients with ECOG PS 2.

- Patients must have at least one measurable lesion, no previously irradiated.

- Life expectancy of at least 12 weeks.

- Adequate organ function according to the following criteria:

- Bone marrow: ANC => 2.0x10(9)cells/L; Platelet count => 100x10(9)cells/L;
Hemoglobin => 10 g/dL.

- Liver function: Bilirubin <= 1.5 X ULN; Alkaline phosphatase <= 5 x ULN; AST and
ALT <= 1.5 x ULN.

- Renal function:serum creatinine <= 2mg/dL.

Exclusion Criteria:

- Prior systemic chemotherapy for advanced disease.

- Prior radiotherapy for NSCLC.

- Patients with symptomatic brain metastases.

- No measurable bone metastases or malignant pleural effusion as only measurable
lesion.

- History of prior malignancies, except curatively treated in situ carcinoma of the
cervix or other cancer curatively treated and with no evidence of disease for at
least five years.

- History of hypersensitivity reaction study drugs.

- Pregnant or lactating women (women of childbearing potential must use adequate
contraception).

- Concurrent treatment with other experimental drugs.

- Current peripheral neuropathy NCI grade 2.

- Participation in clinical trials within 30 days of study entry.

- Major surgery, open biopsy or traumatic lesion 28 days before to study start.